EQRx Reveals Two New Assets For Low-Cost Drug Pipeline
The start-up launched in January with $200m to develop lower-priced drugs against known targets. Now it has licensed a CDK4/6 inhibitor from G1 Therapeutics and an EGFR inhibitor from Hansoh.
The start-up launched in January with $200m to develop lower-priced drugs against known targets. Now it has licensed a CDK4/6 inhibitor from G1 Therapeutics and an EGFR inhibitor from Hansoh.